Kallyope

New Investors TCGX and Viking Global Investors Join World-Class Syndicate Initial Elismetrep Phase 3 Results Anticipated in Mid-2027 Company Relaunching with Key Leadership Appointments and Company Name Change TriGemX Bio (formerly known as Kallyope), a b

NEW YORK, October 01, 2026--TriGemX Bio (formerly known as Kallyope), a biotechnology company focused on developing a first-in-class medicine for the treatment of migraine, today announced the closing of a $94 million financing co-led by The Column Group,

Results contribute to growing body of evidence in support of elismetrep, a TRPM8 migraine-associated channel blocker (MACB), to help address the debilitating impact of migraine Novel liquid-filled softgel capsule (LSGC) formulation results in earlier and

Data validate the efficacy, safety, and tolerability of elismetrep, an investigational first-in-class TRPM8 migraine-associated channel blocker(MACB), as a novel approach for treating migraine Potential for a new mechanism to help address the debilitating

NEW YORK, April 22, 2026--Kallyope is a late-stage biotechnology company focused on developing innovative migraine and metabolic disease therapies for health challenges faced by hundreds of millions of people globally. Today, the Company presented results

Clinically meaningful data establishes proof of concept for elismetrep as a promising therapeutic candidate for migraine and its progression into registrational studies anticipated to initiate mid-2026 Data validate novel TRPM8 migraine-associated channel

PRN_FinancialWrapper